Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest

Journal of Gastrointestinal Surgery

Volumn 15, Issue 11, 2011, Pages 2089-2097

  Demirjian, Aram ^a   Peng, Peter ^a   Geschwind, Jean Francois H ^a   Cosgrove, David ^a   Schutz, Jacob ^a   Kamel, Ihab R ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular; Imaging; Infiltrating; Management; Prognosis

Indexed keywords

TUMOR MARKER;

ARTICLE; BLOOD; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80255133214     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1614-7     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399): 1907-17.
3. Cunningham SC, Tsai S, Marques HP, et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 2009; 16(7): 1820-31.
4. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg; 252(6): 903-912.
5. Okuda K, Noguchi T, Kubo Y, et al. A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver 1981; 1(4): 280-9.
6. Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993; 72(5): 1557-63.
7. Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18(2): 189-95.
8. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286(1): 52-9.
9. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127(5 Suppl 1): S56-61.
10. Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994; 91(6): 2230-4.
11. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22(4 Pt 1): 1027-33.
12. Castells L, Vargas V, Gonzalez A, et al. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995; 15(3): 159-63.
13. Vauthey JN, Walsh GL, Vlastos G, Lauwers GY. Importance of field cancerisation in clinical oncology. Lancet Oncol 2000; 1(1): 15-6.
14. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25(27): 3834-47.
15. Benvegnu L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48(1): 110-5.
16. Myung SJ, Yoon JH, Kim KM, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006; 53(68): 266-70.
17. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101(3): 524-32.
18. Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci; 55(10): 2744-2755.
19. Miyaaki H, Nakashima O, Kurogi M, et al. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007; 42(12): 962-8.
20. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990; 12(6): 1420-32.
21. Tada T, Kumada T, Toyoda H, et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25(4): 848-53.
22. Okuda H, Nakanishi T, Takatsu K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002; 17(7): 772-8.
23. Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol; 105(3): 610-612.
24. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S133-43.
25. de Ledinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002; 14(2): 159-65.
26. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247(2): 311-30.
27. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38(4): 1034-42.
28. Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180(2): 455-60.
29. Kim YK, Han YM, Kim CS. Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Eur J Radiol 2009; 70(1): 94-100.
30. Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology; 254(1): 154-162.
31. Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140(5): 450-7; discussion 57-8.
32. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137(4): 403-10.
33. Han YS, Choi DL, Park JB. Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation-eighteen months of follow-up: a case report. Transplant Proc 2008; 40(8): 2835-6.
34. Ochiai T, Sonoyama T, Ichikawa D, et al. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J Cancer Res Clin Oncol 2004; 130(4): 197-202.
35. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology; 52(2): 762-773.
36. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5): 1164-71.
37. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319): 1734-9.
38. Lopez RR, Jr., Pan SH, Hoffman AL, et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002; 137(6): 653-7; discussion 57-8.
39. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378-90.